Search

Your search keyword '"Kondo, Tadashi"' showing total 763 results
Start Over Author "Kondo, Tadashi" Publication Type Academic Journals
763 results on '"Kondo, Tadashi"'

11. Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcoma

Author

Rasmussen, Samuel V., Wozniak, Agnieszka, Lathara, Melvin, Goldenberg, Joshua M., Samudio, Benjamin M., Bickford, Lissett R., Nagamori, Kiyo, Wright, Hollis, Woods, Andrew D., Chauhan, Shefali, Lee, Che-Jui, Rudzinski, Erin R., Swift, Michael K., Kondo, Tadashi, Fisher, David E., Imyanitov, Evgeny, Machado, Isidro, Llombart-Bosch, Antonio, Andrulis, Irene L., Gokgoz, Nalan, Wunder, Jay, Mirotaki, Hiroshi, Nakamura, Takuro, Srinivasa, Ganapati, Thway, Khin, Jones, Robin L., Huang, Paul H., Berlow, Noah E., Schöffski, Patrick, and Keller, Charles

Published
2023
Full Text
View/download PDF

25. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs

Author

Okimoto, Ross A, Wu, Wei, Nanjo, Shigeki, Olivas, Victor, Lin, Yone K, Ponce, Rovingaile Kriska, Oyama, Rieko, Kondo, Tadashi, and Bivona, Trever G

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biotechnology, Rare Diseases, Orphan Drug, Pediatric Research Initiative, Infectious Diseases, Genetics, Cancer, Aetiology, 2.1 Biological and endogenous factors, Animals, Carcinogenesis, Cell Line, Tumor, Cyclin E, Cyclin-Dependent Kinase 2, Female, Humans, Mice, Mice, SCID, Neoplasm Metastasis, Neoplasms, Experimental, Oncogene Proteins, Oncogene Proteins, Fusion, Proto-Oncogene Proteins c-ets, Sarcoma, Transcription, Genetic, Molecular genetics, Oncology, Medical and Health Sciences, Immunology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Transcription factor fusion genes create oncoproteins that drive oncogenesis and represent challenging therapeutic targets. Understanding the molecular targets by which such fusion oncoproteins promote malignancy offers an approach to develop rational treatment strategies to improve clinical outcomes. Capicua-double homeobox 4 (CIC-DUX4) is a transcription factor fusion oncoprotein that defines certain undifferentiated round cell sarcomas with high metastatic propensity and poor clinical outcomes. The molecular targets regulated by the CIC-DUX4 oncoprotein that promote this aggressive malignancy remain largely unknown. We demonstrated that increased expression of ETS variant 4 (ETV4) and cyclin E1 (CCNE1) occurs via neomorphic, direct effects of CIC-DUX4 and drives tumor metastasis and survival, respectively. We uncovered a molecular dependence on the CCNE-CDK2 cell cycle complex that renders CIC-DUX4-expressing tumors sensitive to inhibition of the CCNE-CDK2 complex, suggesting a therapeutic strategy for CIC-DUX4-expressing tumors. Our findings highlight a paradigm of functional diversification of transcriptional repertoires controlled by a genetically aberrant transcriptional regulator, with therapeutic implications.

Published
2019

42. Harnessing the potential of reverse‐phase protein array technology: Advancing precision oncology strategies.

Author

Masuda, Mari, Nakagawa, Riko, and Kondo, Tadashi

Abstract

The last few decades have seen remarkable strides in the field of cancer therapy. Precision oncology coupled with comprehensive genomic profiling has become routine clinical practice for solid tumors, the advent of immune checkpoint inhibitors has transformed the landscape of oncology treatment, and the number of cancer drug approvals has continued to increase. Nevertheless, the application of genomics‐driven precision oncology has thus far benefited only 10%–20% of cancer patients, leaving the majority without matched treatment options. This limitation underscores the need to explore alternative avenues with regard to selecting patients for targeted therapies. In contrast with genomics‐based approaches, proteomics‐based strategies offer a more precise understanding of the intricate biological processes driving cancer pathogenesis. This perspective underscores the importance of integrating complementary proteomic analyses into the next phase of precision oncology to establish robust biomarker‐drug associations and surmount challenges related to drug resistance. One promising technology in this regard is the reverse‐phase protein array (RPPA), which excels in quantitatively detecting protein modifications, even with limited amounts of sample. Its cost–effectiveness and rapid turnaround time further bolster its appeal for application in clinical settings. Here, we review the current status of genomics‐driven precision oncology, as well as its limitations, with an emphasis on drug resistance. Subsequently, we explore the application of RPPA technology as a catalyst for advancing precision oncology. Through illustrative examples drawn from clinical trials, we demonstrate its utility for unraveling the molecular mechanisms underlying drug responses and resistance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results